Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia

Haematologica

Volumn 85, Issue 11, 2000, Pages 1135-1139

  Zinzani, P L ^a   Bendandi, M ^a   Magagnoli, M ^a   Albertini, P ^a   Rondelli, D ^a   Stefoni, V ^a   Tani, M ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CLL; Fludarabine; Long term follow up; Pretreated

Indexed keywords

FLUDARABINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; VIDARABINE;

EID: 0033658976     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia
2. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia
3. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia
4. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A southeastern Cancer Study Group Trial
5. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment
6. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia
7. The treatment of chronic lymphocytic leukemia with COP chemotherapy
8. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia
9. Treatment of chronic lymphocytic leukemia in advanced stages: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone
10. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia
11. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia
12. Long-term results of CAP therapy in chronic lymphocytic leukemia
13. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia
14. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
15. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
16. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages
17. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia
18. Fludarabine treatment in B-cell chronic lymphocytic leukemia: Response, toxicity and survival analysis in 47 cases
19. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
20. Clinical staging of chronic lymphocytic leukemia
21. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group
22. Non-parametric estimation from incomplete observations
23. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
24. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
25. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia
26. Chronic lymphocytic leukemia: From palliative therapy to curative intent
27. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
28. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
29. Prognostic factors in chronic lymphocytic leukaemia
30. Morphology, atypical chronic lymphocytic leukaemia and prognostic features affecting choice of therapy
31. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders
32. Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphomas